• Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line).
  
• Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line).
  

CLPUB00485
Kuiper C.M., Broxterman H.J., Baas F., Schuurhuis G.J., Haisma H.J., Scheffer G.L., Lankelma J., Pinedo H.M.
Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin.
J. Cell. Pharmacol. 1:35-41(1990)

PubMed=1974823
Baas F., Jongsma A.P.M., Broxterman H.J., Arceci R.J., Housman D.E., Scheffer G.L., Riethorst A., van Groenigen M., Nieuwint A.W.M., Joenje H.
Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
Cancer Res. 50:5392-5398(1990)

PubMed=1348862; DOI=10.1073/pnas.89.8.3498; PMCID=PMC48895
Eijdems E.W.H.M., Borst P., Jongsma A.P.M., de Jong S., de Vries E.G.E., van Groenigen M., Versantvoort C.H.M., Nieuwint A.W.M., Baas F.
Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype.
Proc. Natl. Acad. Sci. U.S.A. 89:3498-3502(1992)

PubMed=1353703
Nieuwint A.W.M., Baas F., Wiegant J., Joenje H.
Cytogenetic alterations associated with P-glycoprotein- and non-P-glycoprotein-mediated multidrug resistance in SW-1573 human lung tumor cell lines.
Cancer Res. 52:4361-4371(1992)